Targeting MIA/CD-RAP dimerization and therefore activity with the inhibitory peptide AR71 has been successfully conducted during melanoma development, and most importantly no adverse effects were observed after an AR71 treatment in mice [16]. This evidence concerns the gene LRPAP1 and melanoma.